MTOR and skin squamous cell carcinoma: However, the benefit of lower CSCC risk with the use of mTOR inhibitors must be balanced with its effectiveness to prevent allograft rejection, the increased risk of cardiovascular events, and the impairment of wound healing which could increase complications if surgical excision or radiation therapy (RT) are planned for the management of CSCC [61].